title: Reduced immunogenic response to residual CHO cell protein in recombinant factor IX (IB1001) drug product in normal healthy rabbits.
authors.affiliation: Research and Development, Cangene Corporation d/b/a Emergent BioSolutions, Winnipeg, MB, Canadaz.
authors.forename: P
authors.initials: P
authors.lastname: Cheung
authors.affiliation: Research and Development, Cangene Corporation d/b/a Emergent BioSolutions, Winnipeg, MB, Canadaz.
authors.forename: A
authors.initials: A
authors.lastname: Emanuel
authors.affiliation: MPI Research, Mattawan, MI, USA.
authors.forename: J
authors.initials: J
authors.lastname: Heward
authors.affiliation: HTI, Essex Junction, VT, USA.
authors.forename: J
authors.initials: J
authors.lastname: Maddalena
authors.affiliation: Research and Development, Cangene Corporation d/b/a Emergent BioSolutions, Winnipeg, MB, Canadaz.
authors.forename: D
authors.initials: D
authors.lastname: Toth
authors.affiliation: Research and Development, Cangene Corporation d/b/a Emergent BioSolutions, Winnipeg, MB, Canadaz.
authors.forename: L
authors.initials: L
authors.lastname: Saward
authors.affiliation: Research and Development, Cangene Corporation d/b/a Emergent BioSolutions, Winnipeg, MB, Canadaz.
authors.forename: S
authors.initials: S
authors.lastname: Kodihalli
mesh_terms: D000818:Animals; D000906:Antibodies / Q000097:blood; D016466:CHO Cells; D045424:Complex Mixtures / Q000276:immunology* / Q000627:therapeutic use; D003412:Cricetulus; D004797:Enzyme-Linked Immunosorbent Assay; D005164:Factor IX / Q000276:immunology* / Q000627:therapeutic use; D005260:Female; D002836:Hemophilia B / Q000188:drug therapy*; D006801:Humans; D056724:Immunity, Humoral; D008297:Male; D015202:Protein Engineering; D011817:Rabbits; D011994:Recombinant Proteins / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D000906:Antibodies; D045424:Complex Mixtures; C579324:IB1001; D011994:Recombinant Proteins; D005164:Factor IX